0001725160-24-000036.txt : 20240205
0001725160-24-000036.hdr.sgml : 20240205
20240205191623
ACCESSION NUMBER: 0001725160-24-000036
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240205
DATE AS OF CHANGE: 20240205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HAUSMAN DIANA
CENTRAL INDEX KEY: 0001563992
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 24597549
MAIL ADDRESS:
STREET 1: C/O ONCOTHYREON INC.
STREET 2: 2601 FOURTH AVE, SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER NAME:
FORMER CONFORMED NAME: HAUSMAN DIANE
DATE OF NAME CHANGE: 20121207
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 823607803
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wk-form4_1707178572.xml
FORM 4
X0508
4
2024-02-01
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001563992
HAUSMAN DIANA
C/O ZENTALIS PHARMACEUTICALS, INC.
1359 BROADWAY, SUITE 801
NEW YORK
NY
10018
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-02-01
4
A
0
337500
0
A
377232
D
Stock Option (Right to Buy)
11.69
2024-02-01
4
A
0
337500
0
A
2034-01-31
Common Stock
337500
337500
D
Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer.
The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
/s/ Andrea Paul, attorney-in-fact for Diana Hausman
2024-02-05